Literature DB >> 3313360

Guillain-Barré neuropathy during treatment with captopril.

T K Chakraborty1, W S Ruddell.   

Abstract

A patient is described who developed acute peripheral neuropathy of Guillain-Barré type occurring shortly after commencement of captopril for moderately severe hypertension and resolving after discontinuation of the drug.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3313360      PMCID： PMC2428261          DOI： 10.1136/pgmj.63.737.221

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  4 in total

1.  Neurological dysfunction in two patients receiving captopril and cimetidine.

Authors:  A B Atkinson; J J Brown; A F Lever; D McAreavey; J I Robertson; P O Behan; I D Melville; A I Weir
Journal:  Lancet       Date:  1980-07-05       Impact factor: 79.321

2.  Captopril: five years on.

Authors:  G P Hodsman; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-24

3.  Effects of prolonged administration of D-penicillamine or captopril in various strains of rats. Brown Norway rats treated with D-penicillamine develop autoantibodies, circulating immune complexes, and disseminated intravascular coagulation.

Authors:  A J Donker; R C Venuto; A O Vladutiu; J R Brentjens; G A Andres
Journal:  Clin Immunol Immunopathol       Date:  1984-01

4.  [Treatment of severe arterial hypertension with captopril (SQ 14.225) (author's transl)].

Authors:  S Di Giulio; J L Perez-Ramirez; P Jamoun; J P Grünfeld; P Meyer
Journal:  Nouv Presse Med       Date:  1981-04-30
  4 in total
  6 in total

1.  Peripheral neuropathy in a patient receiving enalapril.

Authors:  A Hormigo; M Alves
Journal:  BMJ       Date:  1992-11-28

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 3.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

4.  Guillain-Barré syndrome during treatment with ofloxacin.

Authors:  S Schmidt; A Cordt-Schlegel; R Heitmann
Journal:  J Neurol       Date:  1993-09       Impact factor: 4.849

Review 5.  Guillain-Barré syndrome. Clinical manifestations and directions for treatment.

Authors:  J Rees
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 6.  Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?

Authors:  M P Sambhi; H Gavras; J I Robertson; W M Smith
Journal:  West J Med       Date:  1993-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.